Nuformix

1. 25 Aug 26
   Appointment of Chairman

   Nuformix plc (LSE), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce the appointment of Tim Metcalfe as Non-Executive Chairman and a Director of the Company with effect...

   RNS 9737682 ↗
2. 19 Aug 26
   NXP002 Development Update

   Nuformix plc (LSE), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to provide an update on progress with NXP002, the Company's lead programme and a potential novel inhaled...

   RNS 9728512 ↗
3. 28 May 26
   Half-year Results

   Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces its unaudited results for the six months ended 31 March 2026.

   RNS 9588621 ↗
4. 31 Mar 26
   Total Voting Rights

   RNS 9499068 ↗
5. 11 Mar 26
   £1.0 million Placing

   Nuformix plc (LSE:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces a placing (the "Placing") to raise gross proceeds of £1.0 million through the issue of 500,000,000 new...

   RNS 9468093 ↗
6. 10 Mar 26
   Confirmation of US ODD for NXP002 in IPF

   Confirmation of US Orphan Drug Designation for NXP002 Programme in IPF

   RNS 9465863 ↗
7. 03 Mar 26
   Result of AGM

   RNS 9455809 ↗
8. 05 Feb 26
   Posting of Annual Report and Notice of AGM

   RNS 9411698 ↗
9. 27 Jan 26
   Final Results

   Annual Results for the period ended 30 September 2025

   RNS 9388038 ↗
10. 28 Nov 25
    Total Voting Rights

    RNS 9264255 ↗
11. 12 Nov 25
    Update re. US FDA ODD Application

    US FDA Orphan Drug Designation Application for NXP002 Programme in IPF

    RNS 9227860 ↗
12. 12 Nov 25
    Results of Underwritten Open Offer

    Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces the results of its underwritten Open Offer to Qualifying Shareholders which was announced on 28 October...

    RNS 9227667 ↗
13. 28 Oct 25
    Underwritten Open Offer

    Underwritten Open Offer at 0.2p per Open Offer Share to raise £228,081

    RNS 9197709 ↗
14. 10 Oct 25
    Change of Auditor

    Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces the appointment of Kreston Reeves Audit LLP ("Kreston Reeves Audit") as auditor to the Company.

    RNS 9162319 ↗

Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.